Gambaran Umum
Myriad Genetics, Inc., based in the United States, operates prominently within the biotechnology industry, focusing primarily on molecular diagnostics and personalized medicine. Established with the aspiration to advance patient care through genetic insights, Myriad Genetics specializes in developing and marketing predictive, personalized, and prognostic tests across various medical disciplines. Its key projects include pioneering work in hereditary cancer screening, particularly with the BRCA gene tests, and expansions into tests for depression medication response (GeneSight) and rheumatoid arthritis. The company emphasizes innovation in genetic research to facilitate early disease detection and optimized treatment, reflecting its commitment to enhancing patient health outcomes through cutting-edge genetic screening technologies.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Myriad Genetics, Inc. per 2025 Jun 30 adalah 832.90 MM.
- Nilai operating income untuk Myriad Genetics, Inc. per 2025 Jun 30 adalah -76.70 MM.
- Nilai net income untuk Myriad Genetics, Inc. per 2025 Jun 30 adalah -395.20 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 832.90 | -76.70 | -395.20 |
2025-03-31 | 831.30 | -89.10 | -101.40 |
2024-12-31 | 837.60 | -88.00 | -127.30 |
2024-09-30 | 823.60 | -95.40 | -116.00 |
2024-06-30 | 802.20 | -103.30 | -155.20 |
2024-03-31 | 774.20 | -120.30 | -234.60 |
2023-12-31 | 753.20 | -138.90 | -263.30 |
2023-09-30 | 734.40 | -172.20 | -274.40 |
2023-06-30 | 698.90 | -191.40 | -248.20 |
2023-03-31 | 694.70 | -155.90 | -146.20 |
2022-12-31 | 678.40 | -123.70 | -112.00 |
2022-09-30 | 661.40 | -58.80 | -77.30 |
2022-06-30 | 672.30 | -93.70 | -17.60 |
2022-03-31 | 682.40 | -106.30 | -8.20 |
2021-12-31 | 690.60 | -126.70 | -27.20 |
2021-09-30 | 684.40 | -192.70 | -57.50 |
2021-06-30 | 662.30 | -153.50 | -97.30 |
2021-03-31 | 566.10 | -202.80 | -148.00 |
2020-12-31 | 557.00 | -194.80 | -223.70 |
2020-09-30 | 597.50 | -155.30 | -194.10 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah -4.32.
- laba per saham yang terdilusi untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah -4.33.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -4.32 | -4.33 |
2025-03-31 | -1.11 | -1.12 |
2024-12-31 | -1.41 | -1.41 |
2024-09-30 | -1.30 | -1.30 |
2024-06-30 | -1.78 | -1.78 |
2024-03-31 | -2.76 | -2.77 |
2023-12-31 | -3.18 | -3.18 |
2023-09-30 | -3.37 | -3.36 |
2023-06-30 | -3.06 | -3.06 |
2023-03-31 | -1.81 | -1.80 |
2022-12-31 | -1.39 | -1.39 |
2022-09-30 | -0.96 | -0.97 |
2022-06-30 | -0.22 | -0.22 |
2022-03-31 | -0.10 | -0.11 |
2021-12-31 | -0.35 | -0.35 |
2021-09-30 | -0.75 | -0.75 |
2021-06-30 | -1.28 | -1.29 |
2021-03-31 | -1.97 | -1.97 |
2020-12-31 | -2.99 | -2.99 |
2020-09-30 | -2.60 | -2.60 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Myriad Genetics, Inc. per 2025 Jun 30 adalah -22.60 MM.
- Nilai cash from investing activities untuk Myriad Genetics, Inc. per 2025 Jun 30 adalah -13.60 MM.
- Nilai kas dari aktivitas pendanaan untuk Myriad Genetics, Inc. per 2025 Jun 30 adalah 15.20 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -22.60 | -13.60 | 15.20 |
2025-03-31 | -6.40 | -13.10 | 15.00 |
2024-12-31 | -8.70 | -11.90 | -7.40 |
2024-09-30 | -70.00 | -18.00 | 112.40 |
2024-06-30 | -92.80 | -28.00 | 113.00 |
2024-03-31 | -96.30 | -9.80 | 149.00 |
2023-12-31 | -110.90 | 31.90 | 152.90 |
2023-09-30 | -63.50 | 8.30 | 28.90 |
2023-06-30 | -44.20 | 22.20 | 27.80 |
2023-03-31 | -93.00 | -1.60 | -8.10 |
2022-12-31 | -106.30 | -77.50 | -8.00 |
2022-09-30 | -108.50 | -67.80 | -7.00 |
2022-06-30 | -145.00 | 211.80 | -77.90 |
2022-03-31 | -99.70 | 224.90 | -106.90 |
2021-12-31 | 18.60 | 274.40 | -150.60 |
2021-09-30 | 13.70 | 311.30 | -147.70 |
2021-06-30 | -6.30 | 37.30 | -77.10 |
2021-03-31 | 28.10 | 46.60 | -49.70 |
2020-12-31 | -26.90 | 61.60 | -1.00 |
2020-09-30 | -14.40 | 43.50 | -1.60 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah -4.83.
- p/libro untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah 0.69.
- p/tbv untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah 3.04.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -4.83 | 0.69 | 3.04 |
2025-03-31 | 1.16 | 5.32 | |
2024-12-31 | 1.70 | 9.34 | |
2024-09-30 | -15.48 | 3.25 | 17.84 |
2024-06-30 | -9.43 | 2.91 | 16.75 |
2024-03-31 | 2.44 | 13.08 | |
2023-12-31 | -6.18 | 2.48 | 42.19 |
2023-09-30 | -5.29 | 1.79 | 14.72 |
2023-06-30 | -12.82 | 2.24 | 10.49 |
2023-03-31 | -16.83 | 2.13 | |
2022-12-31 | 1.28 | 3.80 | |
2022-09-30 | 1.63 | 4.71 | |
2022-06-30 | 1.54 | 4.59 | |
2022-03-31 | -74.14 | 2.08 | 6.21 |
2021-12-31 | 36.75 | 2.28 | 7.02 |
2021-09-30 | 124.85 | 2.79 | 10.71 |
2021-06-30 | |||
2021-03-31 | -54.92 | 1.91 | -128.86 |
2020-12-31 | -7.36 | 1.87 | -66.67 |
2020-09-30 | -8.46 | 1.81 | -165.90 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah -0.28.
- EBIT (3 tahun) / EV untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah -0.40.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.28 | -0.40 |
2025-03-31 | -0.17 | -0.23 |
2024-12-31 | -0.10 | -0.15 |
2024-09-30 | -0.07 | -0.08 |
2024-06-30 | -0.11 | -0.07 |
2024-03-31 | -0.14 | -0.08 |
2023-12-31 | -0.17 | -0.08 |
2023-09-30 | -0.21 | -0.10 |
2023-06-30 | -0.09 | -0.05 |
2023-03-31 | -0.08 | -0.07 |
2022-12-31 | -0.12 | -0.11 |
2022-09-30 | -0.03 | -0.06 |
2022-06-30 | -0.03 | -0.08 |
2022-03-31 | -0.03 | -0.06 |
2021-12-31 | 0.02 | -0.03 |
2021-09-30 | -0.02 | -0.04 |
2021-06-30 | ||
2021-03-31 | -0.06 | -0.05 |
2020-12-31 | -0.16 | -0.05 |
2020-09-30 | -0.14 | -0.04 |
Efektivitas Manajemen
- roa untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah -0.09.
- roe untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah -0.14.
- roic untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah -0.12.
- croic untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah -0.01.
- ocroic untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah -0.01.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.09 | -0.14 | -0.12 | -0.01 | -0.01 |
2025-03-31 | -0.11 | -0.17 | -0.15 | -0.03 | -0.01 |
2024-12-31 | -0.10 | -0.15 | -0.13 | 0.03 | -0.08 |
2024-09-30 | -0.14 | -0.23 | -0.18 | -0.01 | -0.11 |
2024-06-30 | -0.20 | -0.28 | -0.26 | 0.05 | -0.11 |
2024-03-31 | -0.22 | -0.30 | -0.28 | 0.08 | -0.12 |
2023-12-31 | -0.23 | -0.30 | -0.31 | -0.03 | -0.07 |
2023-09-30 | -0.21 | -0.26 | -0.26 | 0.01 | -0.05 |
2023-06-30 | -0.12 | -0.15 | -0.28 | 0.01 | -0.05 |
2023-03-31 | -0.09 | -0.12 | -0.15 | -0.10 | -0.09 |
2022-12-31 | -0.06 | -0.08 | -0.07 | -0.18 | -0.10 |
2022-09-30 | -0.01 | -0.02 | -0.07 | -0.18 | -0.10 |
2022-06-30 | -0.01 | -0.01 | -0.02 | -0.01 | -0.14 |
2022-03-31 | -0.02 | -0.03 | -0.01 | 0.02 | -0.10 |
2021-12-31 | 0.04 | 0.07 | -0.02 | 0.12 | -0.09 |
2021-09-30 | 0.01 | 0.02 | 0.05 | 0.04 | -0.11 |
2021-06-30 | 0.01 | 0.02 | 0.02 | -0.14 | -0.10 |
2021-03-31 | -0.02 | -0.03 | -0.14 | 0.03 | -0.08 |
2020-12-31 | -0.14 | -0.21 | -0.19 | 0.03 | -0.13 |
2020-09-30 | -0.12 | -0.18 | -0.16 | 0.02 | -0.01 |
Gross Margins
- marjin kotor untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah 0.70.
- marjin bersih untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah -0.12.
- marjin operasi untuk Myriad Genetics, Inc. pada 2025 Jun 30 adalah -0.11.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | 0.70 | -0.12 | -0.11 |
2025-03-31 | 0.70 | -0.15 | -0.10 |
2024-12-31 | 0.69 | -0.14 | -0.12 |
2024-09-30 | 0.69 | -0.19 | -0.13 |
2024-06-30 | 0.69 | -0.30 | -0.15 |
2024-03-31 | 0.69 | -0.35 | -0.19 |
2023-12-31 | 0.69 | -0.37 | -0.22 |
2023-09-30 | 0.68 | -0.36 | -0.26 |
2023-06-30 | 0.69 | -0.36 | -0.26 |
2023-03-31 | 0.70 | -0.21 | -0.23 |
2022-12-31 | 0.70 | -0.12 | -0.09 |
2022-09-30 | 0.71 | -0.12 | -0.09 |
2022-06-30 | 0.71 | -0.03 | -0.14 |
2022-03-31 | 0.72 | -0.01 | -0.14 |
2021-12-31 | 0.72 | -0.04 | -0.18 |
2021-09-30 | 0.72 | 0.08 | -0.22 |
2021-06-30 | 0.72 | 0.03 | -0.18 |
2021-03-31 | 0.70 | -0.26 | -0.36 |
2020-12-31 | 0.70 | -0.40 | -0.34 |
2020-09-30 | 0.70 | -0.32 | -0.27 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 899923 |
Grupong Pang-industriya
SIC 2835 - In Vitro and In Vivo Diagnostic Substances |